Revolution Medicines’ pan-RAS inhibitor daraxonrasib delivered a survival gain in the Phase 3 RASolute 302 study for advanced pancreatic ductal adenocarcinoma. In a trial of 500 patients previously treated with chemotherapy, median survival was 13.2 months with daraxonrasib versus 6.7 months with investigator-selected chemotherapy. The drug also improved progression metrics, with no disease worsening for 7.2 months compared with 3.6 months in the chemotherapy arm. Results were published alongside presentations at ASCO 2026 and were framed by investigators and outside experts as potentially practice-changing. For a malignancy with limited effective options, the trial reinforces momentum around targeting RAS pathway biology more broadly rather than focusing on single KRAS variants.